The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Joshua James Gruber
Employment - Guardant Health (I)
Stock and Other Ownership Interests - Guardant Health (I)
Honoraria - bioTheranostics
Consulting or Advisory Role - Sharma Therapeutics, LLC
Patents, Royalties, Other Intellectual Property - HAT1 inhibitor patents
 
Melinda L. Telli
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Guardant Health; Merck; Natera; Novartis; OncoSec; Reflexion Medical; Replicate Bioscience; Sanofi
Research Funding - Abbvie (Inst); Arvinas (Inst); Bayer (Inst); Biothera (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); OncoSec (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst); Vertex (Inst)
Other Relationship - G1 Therapeutics; Immunomedics
 
Monica M. Mita
No Relationships to Disclose
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Joseph W. Kim
Consulting or Advisory Role - Clovis Oncology; EMD Serono; Halda Therapeutics; Janssen Biotech; Sanofi
Research Funding - ADC Therapeutics (Inst); Cosmo Pharmaceuticals; Exelixis (Inst); Hummingbird (Inst); Regeneron (Inst); Roche (Inst)
 
Miguel Angel Villalona-Calero
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Lilly
Speakers' Bureau - Amgen
Research Funding - Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Merck (Inst); Novocure (Inst); Tolero Pharmaceuticals (Inst)
 
Meera Patel
No Relationships to Disclose
 
Shalini S. Yadav
No Relationships to Disclose
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Tom Haber
Employment - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Jessica Lauren Symons
Consulting or Advisory Role - Hummingbird
 
Qihui Seet
Employment - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Bhushan Dharmadhikari
Employment - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Patents, Royalties, Other Intellectual Property - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Dipti Thakkar
Employment - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Patents, Royalties, Other Intellectual Property - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Kon Yew Kwek
Employment - Akeso Biopharma
 
Leah DiMascio
Employment - Hummingbird
Leadership - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Eric Keith Rowinsky
Employment - Hummingbird
Leadership - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Piers Ingram
Employment - Hummingbird
Leadership - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Patents, Royalties, Other Intellectual Property - Hummingbird
Travel, Accommodations, Expenses - Hummingbird
 
Jerome Douglas Boyd-Kirkup
Employment - Hummingbird
Leadership - Hummingbird
Stock and Other Ownership Interests - Hummingbird
Patents, Royalties, Other Intellectual Property - Hummingbird
Travel, Accommodations, Expenses - Hummingbird